3D Medicines Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 35.42 | -100% | 0 | 0% |
| P/S |
|
2.76 | 7.59 | -63.63% |
|
|
| P/BV |
|
9.43 | 3.68 | 155.91% |
|
|
| P/FCF |
|
0 | 55.3 | -100% |
|
|
| Ev/Ebitda |
|
-8.57 | 2.91 | -394.71% |
|
|
| Ev/S |
|
15.51 | 23.72 | -34.6% |
|
|
| Ev/FCF |
|
0 | 63.78 | -100% |
|
|
| E/P |
|
-0.1059 | 0.0326 | -424.54% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-77.67 | -11.9 | 552.6% | 0 | 0% |
| ROE |
|
0 | 5.19 | -100% |
|
|
| ROA |
|
-23.03 | 3.47 | -763.77% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
-179.77 | -11.49 | 1465% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 0.7755 | -100% | 0 | 0% |
| Nеt Debt/Ebitda |
|
0 | 0.0127 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.1229 | -100% |
|
|
| Debt/Equity |
|
0 | 0.802 | -100% |
|
|
| Debt/Net Income |
|
0 | 1.76 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 2.43 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.563 | -100% |
|
|
| Average dividend growth |
|
0 | 3.2 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.82 | -100% |
|
|
| Average percentage for payments |
|
0 | 23.96 | -100% |
|
|
| Difference from average difference in sector |
|
-2.43 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 28.69 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
0 | -40.52 | -100% | ||
| Growth impulse Net Income in 5 years |
|
0 | 94.84 | -100% | ||
| Growth impulse FCF in 5 years |
|
0 | 91.41 | -100% | ||
| Growth impulse EPS in 5 years |
|
0 | -118.14 | -100% |
IP Score
2.85/10
